[
  {
    "ts": null,
    "headline": "Wall Street Optimism Pushes J&J Toward $500 Billion Market Value",
    "summary": "The stock is on a 13-session winning streak, J&J’s longest ever, and is up 9.9% in November, putting it on pace for its best month since April 2020.  Wall Street is becoming increasingly optimistic about the company’s plans to plug revenue holes following patent expiration for its top-selling psoriasis drug, Stelara.",
    "url": "https://finnhub.io/api/news?id=34288ef290d6c226782c5797b200ea2698528c33bc6b7f46bd53e20b9d46ebda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764192715,
      "headline": "Wall Street Optimism Pushes J&J Toward $500 Billion Market Value",
      "id": 137619060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The stock is on a 13-session winning streak, J&J’s longest ever, and is up 9.9% in November, putting it on pace for its best month since April 2020.  Wall Street is becoming increasingly optimistic about the company’s plans to plug revenue holes following patent expiration for its top-selling psoriasis drug, Stelara.",
      "url": "https://finnhub.io/api/news?id=34288ef290d6c226782c5797b200ea2698528c33bc6b7f46bd53e20b9d46ebda"
    }
  },
  {
    "ts": null,
    "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
    "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
    "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764176336,
      "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
      "id": 137615519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407294139/image_1407294139.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
      "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4"
    }
  },
  {
    "ts": null,
    "headline": "DGRO Is A Wealth Compounding Machine, But Nobody Is Talking About Its Biggest Weakness",
    "summary": "iShares Core Dividend Growth ETF has a strong track record as a dividend growth and wealth compounding machine. Learn more about DGRO ETF here.",
    "url": "https://finnhub.io/api/news?id=8ef53e17862ee1b6645c4de1626468fe4d1ce398dcc0c20a67e8420055c47935",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764175368,
      "headline": "DGRO Is A Wealth Compounding Machine, But Nobody Is Talking About Its Biggest Weakness",
      "id": 137615461,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223205906/image_2223205906.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "iShares Core Dividend Growth ETF has a strong track record as a dividend growth and wealth compounding machine. Learn more about DGRO ETF here.",
      "url": "https://finnhub.io/api/news?id=8ef53e17862ee1b6645c4de1626468fe4d1ce398dcc0c20a67e8420055c47935"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
    "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
    "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174517,
      "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
      "id": 137615429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009808479/image_2009808479.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
      "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b"
    }
  },
  {
    "ts": null,
    "headline": "Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3",
    "summary": "The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.",
    "url": "https://finnhub.io/api/news?id=db39aae16a94e09e79bbfa64f29e6d63783bca69a521d5b87ef328887328a284",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764154047,
      "headline": "Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3",
      "id": 137614463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.",
      "url": "https://finnhub.io/api/news?id=db39aae16a94e09e79bbfa64f29e6d63783bca69a521d5b87ef328887328a284"
    }
  },
  {
    "ts": null,
    "headline": "CMS covers cardiac ablation in ambulatory surgery centers",
    "summary": "Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.",
    "url": "https://finnhub.io/api/news?id=6d440735b566829ab45e64cd097b3e653a62f1a7d2d3619242969edc52973bdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764151131,
      "headline": "CMS covers cardiac ablation in ambulatory surgery centers",
      "id": 137614465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.",
      "url": "https://finnhub.io/api/news?id=6d440735b566829ab45e64cd097b3e653a62f1a7d2d3619242969edc52973bdc"
    }
  },
  {
    "ts": null,
    "headline": "Is Kenvue’s Share Price a Bargain After 13.5% Jump and New Product Launches?",
    "summary": "Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught some attention lately, climbing 4.9% over the last week and jumping 13.5% for the past month. This comes despite a drop of 20.0% year-to-date and 26.5% over the last year. In recent weeks, headlines have highlighted Kenvue’s continued integration efforts...",
    "url": "https://finnhub.io/api/news?id=0f56e1f0982887b1b794f8bda0ef9ec076a2491d1779a6dd34a65f7cbc495f72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764131282,
      "headline": "Is Kenvue’s Share Price a Bargain After 13.5% Jump and New Product Launches?",
      "id": 137611248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught some attention lately, climbing 4.9% over the last week and jumping 13.5% for the past month. This comes despite a drop of 20.0% year-to-date and 26.5% over the last year. In recent weeks, headlines have highlighted Kenvue’s continued integration efforts...",
      "url": "https://finnhub.io/api/news?id=0f56e1f0982887b1b794f8bda0ef9ec076a2491d1779a6dd34a65f7cbc495f72"
    }
  }
]